Wyeth buys Thiakis for $150 million
This article was originally published in Scrip
Executive Summary
Wyeth has bought Thiakis, a privately-held UK biotechnology company focused on obesity, for $150 million to boost its portfolio of metabolic disorder treatments. Imperial Innovations, a UK technology commercialisation and investment company that had a 23.7% stake in Thiakis, may receive a net cash payment of £22.2 million from the sale, and has rights to royalties on sales. Thiakis is developing TKS1225, an analogue of the peptide hormone oxyntomodulin, for obesity, including conditions associated with excess weight, such as type 2 diabetes and cardiovascular disease. Imperial retains the rights to royalties on sales of Thiakis products. Thiakis was founded in 2004 and raised £10 million from a syndicate of investors in 2006.
You may also be interested in...
Innovation not M&A to drive Bayer growth in LatAm
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
2010 Scrip 100 - Is Anvisa a friend of innovators?
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan raises $1.5 billion
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.